Advertisement
Canada markets close in 4 hours 18 minutes
  • S&P/TSX

    21,869.60
    -142.12 (-0.65%)
     
  • S&P 500

    5,064.03
    -6.52 (-0.13%)
     
  • DOW

    38,364.87
    -138.82 (-0.36%)
     
  • CAD/USD

    0.7287
    -0.0033 (-0.45%)
     
  • CRUDE OIL

    82.71
    -0.65 (-0.78%)
     
  • Bitcoin CAD

    88,946.69
    -2,439.75 (-2.67%)
     
  • CMC Crypto 200

    1,402.21
    -21.89 (-1.54%)
     
  • GOLD FUTURES

    2,342.60
    +0.50 (+0.02%)
     
  • RUSSELL 2000

    1,989.97
    -12.67 (-0.63%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ

    15,723.11
    +26.47 (+0.17%)
     
  • VOLATILITY

    16.10
    +0.41 (+2.61%)
     
  • FTSE

    8,038.74
    -6.07 (-0.08%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6815
    -0.0021 (-0.31%)
     

Stocks - FAANGs Slide in Premarket, Teva Sinks, Uber Extends Losses

Investing.com - Stocks in focus in premarket trade Monday:

• FAANG stocks Facebook (NASDAQ:FB), Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), Netflix (NASDAQ:NFLX) and Google (NASDAQ:GOOGL) all slid between 2% and 3% by 8:16 AM ET (12:16 GMT) as the high-value tech stocks were hit by concerns that the tariff battle between the U.S. and China would hit their profits.

• Uber (NYSE:UBER) stock tumbled 6.9%, extending the decline of nearly 8% that the company registered on its first day of trade last Friday. Its ride-hailing rival Lyft (NASDAQ:LYFT) was indicated to open down another 3.1% - a loss of 30% from its IPO price in March.

• Teva Pharmaceutical (NYSE:TEVA) stock sank 8.7% after the company was named in a lawsuit for allegedly fixing drug prices.

ADVERTISEMENT

• Walt Disney (NYSE:DIS) stock fell 1.5% amid risk-off sentiment despite the fact that its “Avengers: Endgame” continued to rake in the money at the box office for a third consecutive weekend.

• Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 17.8% after reporting a much narrower loss than expected for the first quarter. The stock still remains nearly 50% below the level it was at when the Food & Drug Administration approved a drug last week that competes with Catalyst's Firdapse.

Related Articles

WestJet to be taken private in C$3.5 billion cash deal

Bed Bath & Beyond CEO Steven Temares steps down

Futures extend losses after China plans retaliation